Lyra Therapeutics Q3 net loss $14.8M; pauses ENLIGHTEN II enrollment for in-house mfg

Lyra Therapeutics, Inc.

2022-Q3 EPS reported -$1.47 revenue$1,352,000

Net loss of $14.8M for Q3 2022, compared to $11.1M in Q3 2021.
Cash and equivalents $109.6M; expected to fund operations through mid-2024.
ENLIGHTEN I Phase 3 trial on track for enrollment completion mid-2023; ENLIGHTEN II paused, resuming Q3 2023.
BEACON Phase 2 trial of LYR-220 advanced to randomized stage; initial data submitted for 2023 meeting.
R&D expenses rose to $10.0M from $7.1M year-over-year due to clinical trial costs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Lyra Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022 was $14.8 million.

Period: the third quarter ended September 30, 2022
Net income: Net loss for the quarter ended September 30, 2022 was $14.8 million
Result: reported results

Exact text from the filing

On November 8, 2022, Lyra Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.